Skip to main content

Table 2 Summary of univariate analysis

From: Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer

Characteristics N Mean RFS (years) 95% CI p value for LR Mean OS (years) 95% CI p value for LR
Age (range)        
< 40 years 15 8.1 6.3-10.0   10.6 10.1-11.1  
40-55 years 82 11.1 10.5-11.7   11.2 10.7-11.8  
> 55 years 110 10.3 9.6-11.1 0.084 10.2 9.5-10.9 0.051
Tumor size        
T1 121 11.1 10.6-11.7   11.1 10.6-11.7  
T2 76 10.0 9.1-10.8   10.5 9.9-11.2  
T3-T4 10 6.1 2.9-9.4 < 0.001 6.6 3.6-9.6 < 0.001
Lymph node        
Negative 106 11.0 10.5-11.7   11.2 10.7-11.7  
Positive 101 10.0 9.2-10.7 0.031 10.1 9.4-10.8 0.030
Histology        
Ductal 173 10.6 10.0-11.1   10.6 10.1-11.1  
Lobular 24 10.5 9.1-11.9   11.5 10.8-12.3  
Other 10 9.8 7.4-12.3 0.722 10.4 7.8-12.9 0.410
Tumor grade (Scarff-Bloom-Richardson)        
I 52 11.9 11.4-14.4   11.7 11.1-12.3  
II 96 10.4 9.6-11.1   10.6 10.0-11.2  
III 59 9.4 8.2-11.1 0.003 9.9 8.9-10.9 0.024
Estrogen receptor        
Negative 53 9.6 8.4-10.7   10.2 9.2-11.2  
Positive 153 11.0 10.5-11.5 0.012 11.0 10.5-11.5 0.354
Progesterone receptor        
Negative 61 9.5 8.4-10.6   9.9 9.0-10.9  
Positive 145 11.1 10.6-11.6 0.013 11.2 10.7-11.6 0.035
Her2-neu expression (IHC)        
0, 1+ or 2+ 182 10.6 10.1-11.1   10.7 10.3-11.2  
3+ 22 9.7 8.4-10.9 0.819 10.1 9.2-11.0 0.886
CCR6 on tumor cells        
Negative 130 11.0 10.4-11.6   10.9 10.3-11.4  
Positive 72 9.9 9.0-10.8 0.032 10.5 9.8-11.2 0.400
CCR7 on stromal cells        
Negative 118 10.8 10.2-11.5   11.0 10.5-11.6  
Positive 89 10.3 9.4-11.1 0.344 10.4 9.6-11.1 0.153
CCL19 on tumor cells        
Negative 95 10.4 9.6-11.2   10.7 10.0-11.3  
Positive 109 10.7 10.0-11.4 0.730 10.8 10.2-11.4 0.962
CCL19 on dendritic cells        
Negative 103 11.0 10.4-11.7   11.0 10.3-11.5  
Positive 101 9.8 9.1-10.6 0.042 10.2 9.6-10.9 0.271
  1. IHC: assessed by immunohistochemistry.